JHOP - December 2018 Vol 8, No 4
Comparing Outcomes in Patients with Recurrent or Refractory Ovarian Cancer Managed with 1 of 2 Versions of Pegylated Liposomal Doxorubicin at an Academic Medical Center
Review of PD-1–Induced Myositis and a Case of Pembrolizumab-Induced Myositis in a Patient with Metastatic Melanoma
Immune checkpoint inhibitors, including programmed-cell death (PD)-1 and cytotoxic T-lymphocyte–associated protein (CTLA)-4 inhibitors, have proved to be effective in treating many cancers, but in rare cases, have been reported to cause fatal and life-threatening immune-mediated adverse events (AEs).
Results 1 - 4 of 4